Trial · NCT03415152
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Adherence Rate at the End of the Study (Visit 3) | 6 months | Population of patients registered in electronic system and reported Omacor administration | proportion of days | MEAN |
| SECONDARY | Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) at the End of the Study (Visit 3) | 6 months | Population of patients attended at Visit 3 (month 6) | score on a scale | MEAN |
| SECONDARY | The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination | 6 months | percentage of participants | NUMBER | |
| SECONDARY | The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | 3 months, 6 months | Population of patients registered in electronic system and reported Omacor administration | score on a scale | MEAN |
| SECONDARY | Change of Lipid Profile Parameters at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | 3 months, 6 months | Per protocol population: patients who attended at least one follow-up visit. | mmol/L | MEAN |
| SECONDARY | Number of Hospitalizations Due to Cardio-vascular Reasons During 6 Months of the Program | 6 months | percentage of participants | NUMBER | |
| SECONDARY | Number of New Cases of Stenocardia During 6 Months of the Program | 6 months | percentage of participants | NUMBER | |
| SECONDARY | Number of Non-fatal Myocardial Infarction Cases During 6 Months of the Program | 6 months | percentage of participants | NUMBER | |
| SECONDARY | Number of Cases of Cardio-vascular Death During 6 Months of the Program | 6 months | percentage of participants | NUMBER | |
| SECONDARY | Mean Adherence Rate at Visit 2 | 3 months | Population of patients registered in electronic system and reported Omacor administration | proportion of days | MEAN |
| SECONDARY | Change of Mean Adherence Rate by End of the Study (Visit 3) Versus Visit 2 | 3 months, 6 months | Population of patients registered in electronic system and reported Omacor administration | proportion of days | MEAN |
| SECONDARY | The Percentage of Patients With Adherence Rate <0,5, 0,5-0,7, ≥0,8 at Visit 2 and Visit 3 | 3 months, 6 months | Population of patients registered in electronic system and reported Omacor administration | percentage of participants | NUMBER |
| SECONDARY | Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) [9] at Visit 1, Visit 2 | 0 months, 3 months | Per protocol population: patients who attended at least one follow-up visit | score on a scale | MEAN |
| SECONDARY | Change of Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) [9] at Visit 2 and Visit 3 Versus Baseline (Visit 1) | Baseline, 3 Months, 6 Months | Per protocol population: patients who attended at least one follow-up visit | score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03415152/outcomes